Valerian Root Dosage for Sleep: What the Evidence Says

Valerian root is unusual among sleep herbs: its dose is properly attributable to a federal source. The U.S. National Center for Complementary and Integrative Health (NCCIH) states that valerian has been used with apparent safety at 300–600 mg daily for up to 6 weeks — and in the same breath says there is not enough evidence to determine whether valerian is useful for any health conditions. In 2017, the American Academy of Sleep Medicine recommended against valerian for chronic insomnia in adults.

This guide maps dose-by-goal honestly: what was studied, what our remedy page says, and where the evidence stops.

Evidence-Based Guide | Sleep Health

About Valerian Root

Valerian (Valeriana officinalis) is a flowering plant native to Europe and Asia whose root has been used for centuries as a calming and sleep aid. Its proposed mechanism is modulation of GABA signaling — the brain's main inhibitory neurotransmitter system — which is why it is often described as "nature's benzodiazepine." That description is a hypothesis about mechanism, not a demonstrated equivalence: valerian has never been shown to act like a benzodiazepine in humans — a fair characterization (valerenic acid modulates GABA-A at the beta+alpha subunits, not the benzodiazepine binding site).

NCCIH's valerian page states: "It has been used with apparent safety in doses of 300 to 600 milligrams daily for up to 6 weeks"; "The safety of long-term use of valerian is unknown"; and "There is not enough evidence to determine whether valerian is useful for any health conditions" (May 2025 page).

The Honest Evidence Picture

Read this before you buy anything. Valerian is one of the most-studied sleep herbs — and the verdict is unflattering.

• NCCIH (NIH): "There is not enough evidence to determine whether valerian is useful for any health conditions" — including insomnia (exact NCCIH wording, May 2025 page).
• American Academy of Sleep Medicine (2017): The AASM's clinical practice guideline for chronic insomnia in adults recommended against the use of valerian (weak recommendation; evidence quality low, range very low to moderate). The recommendation rested on two trials: Morin et al. (valerian 374 mg + hops 83.8 mg, 28 days) and Oxman et al. (valerian 3,600 mg, n=405, no significant improvement).
• *Bent et al. (2006, American Journal of Medicine):* A systematic review and meta-analysis of randomized, placebo-controlled trials of valerian for insomnia — 16 studies in the review (1,093 patients), 6 in the meta-analysis. Pooled RR of improved sleep 1.8 (95% CI 1.2–2.9), with evidence of publication bias. The abstract concludes valerian 'might improve sleep quality without producing side effects'; the full text stresses methodologic problems that limit firm conclusions.
• *Donath et al. (2000, Pharmacopsychiatry):* A randomized, double-blind, placebo-controlled crossover trial (n=16, psychophysiological insomnia). A single dose had no effect on sleep structure or subjective sleep quality; after 14 days there was a statistically significant reduction in slow-wave-sleep latency and increased SWS% vs placebo — but subjective benefit was only a non-significant 'tendency' toward shorter subjective sleep latency. The authors recommend valerian for mild psychophysiological insomnia.
• LiverTox cited-reference annotation: Schroeck et al. 2016's review of sleep medicines in older adults (Clin Ther 38:2340-2372) is summarized in LiverTox's reference notes as: "Valerian and melatonin are unregulated products that have a small impact on sleep latency and can produce residual sedation." Note: this applies to valerian AND melatonin together — it is not a LiverTox-authored body statement about valerian alone.
• Menopause: Three small studies suggest valerian might help menopausal symptoms including sleep disturbance: Taavoni et al., Menopause 2011;18(9):951–955 (100 postmenopausal women, 530 mg nightly × 4 weeks, sleep); Mirabi & Mojab, Iran J Pharm Res 2013;12(1):217–222 (hot flashes); Jenabi et al., Women Health 2018;58(3):297–304 (hot flashes, triple-blind RCT). NCCIH's exact wording: "Three small studies suggest that valerian might be helpful for menopause symptoms, but there is not enough evidence to know for certain."

The pattern across the literature: modest, inconsistent signals on subjective sleep quality; no consistent effect on objective sleep measures; and a federal guideline recommending against it for chronic insomnia. Valerian may be a reasonable experiment for occasional, stress-related sleeplessness — it is not an evidence-based treatment for insomnia.

Dose by Goal

Forms: Extract vs Tea vs Tincture

• Standardized extract (capsules/tablets): The form with the most trial data behind it. But "standardized" varies by manufacturer — the federal mg ranges were reported without specifying extract type, solvent, or standardization, so 300 mg from one brand is not the same product as 300 mg from another.
• Dried root tea: Traditional preparation; no controlled trial has tested a tea dose. The aromatic volatile oils (part of the proposed active fraction) are partly lost in hot water.
• Tincture (alcohol extract): Common in herbal practice; trial evidence is thin. Alcohol-based extracts raise the same comparability problem — no standardization anchor.
• Combination products: Valerian is frequently sold blended with hops, lemon balm, passionflower, or chamomile. These blends have their own (mostly untested) profiles; don't attribute a blend's effect to valerian alone.

Safety, Side Effects & Interactions

Do not take indefinitely. The 6-week ceiling is a ceiling on the safety evidence, not a treatment course — long-term safety is unknown.

Do not expect proven efficacy for insomnia. Trials show inconsistent results; the AASM 2017 guideline recommended against valerian for chronic insomnia in adults.

Side effects: Headache, dizziness, stomach upset, and mental dullness are the commonly reported effects. Paradoxical excitability or uneasiness and morning grogginess have been reported, particularly at higher doses. Occasional paradoxical stimulation (excitability, restlessness) and next-morning drowsiness are reported, with residual effects appearing dose-dependent; excitability and uneasiness are listed as uncommon side effects (NCCIH/Drugs.com). No specific mg threshold for these effects is established in the literature.

Liver: Valerian has been implicated in rare case reports of liver injury, usually in multi-ingredient products or with co-medications — causality is generally unclear. Two distinct cases are on record. Kia et al. 2016 (Intern Med J; PMID 26813905): a 57-year-old man developed jaundice 2 weeks after taking 3 tablets of a cold medication containing 2 g of valerian per tablet (bilirubin 5.1 mg/dL, ALT 1191 U/L, Alk P 221 U/L, INR 1.3); enzymes did not improve over 4 weeks, prednisolone was added, and the injury resolved promptly — LiverTox titles this 'valerian-associated hepatitis.' The indapamide case is separate (a woman on chronic indapamide, per the site's remedy page); do not combine the two. LiverTox assigns valerian "Likelihood score: C (probable rare cause of clinically apparent liver injury)."

Interactions (ask your clinician):

• Alcohol and sedatives (benzodiazepines, z-drugs, sleep aids) — the only interaction class named by NCCIH; over-sedation risk. LiverTox gives a mechanistic rationale (believed GABA-receptor interaction similar to benzodiazepines) — a belief, not a demonstrated interaction.
• Surgery: Tell your anesthesiologist; the American Society of Anesthesiologists advises stopping all herbal medications 2–3 weeks before surgery. No valerian-specific discontinuation window is established (a JAMA 2001 perioperative review listed valerian as 'no data' — no window could be set).
• No CYP enzyme, transporter, or named prescription drug is implicated in the sources read for the site page — absence of documented interaction is not demonstrated safety.
• Pregnancy and breastfeeding: NCCIH's exact wording: "Little is known about whether it's safe to use valerian during pregnancy or while breastfeeding." Avoid unless a clinician advises otherwise — but note this is precautionary, not an NCCIH avoidance recommendation.

What to Look For on the Label

• *Root of Valeriana officinalis specified — other species (e.g., Indian valerian / Tagara, Valeriana wallichii*) circulate under the same common name.
• Extract type and standardization stated — the federal sources give mg ranges without any extract/solvent/standardization specification, so comparability is inherently limited. A label that states these is more trustworthy than one that doesn't.
• Avoid multi-ingredient "relaxation" beverages/blends as a valerian dose — Stacy (J Child Adolesc Psychopharmacol 2011) counted more than 300 relaxation beverages in the US overall, only SOME of which include valerian as an anxiolytic/sleep aid (brands like Drank, iChill, Slow Cow); contents are uncontrolled.
• Third-party testing (USP, NSF, ConsumerLab) for identity and contaminants — standard supplement-quality advice.

📢 Disclaimer: This information is for educational purposes only and is not medical advice. Always consult a qualified healthcare professional before starting any new supplement. Sources are linked for verification.

Explore the Full Remedy Database

Browse 500+ organic alternatives for health, wellness, and natural living.